Results 61 to 70 of about 5,561 (207)

Preclinical models for evaluating psychedelics in the treatment of major depressive disorder

British Journal of Pharmacology, EarlyView.
Psychedelic drugs have seen a resurgence in interest as a next generation of psychiatric medicines with potential as rapid‐acting antidepressants (RAADs). Despite promising early clinical trials, the mechanisms which underlie the effects of psychedelics are poorly understood.
Laith Alexander, Dasha Anderson, Luke Baxter, Matthew Claydon, James Rucker, Emma S. J. Robinson   +5 more
wiley   +1 more source

The Australia story: Current status and future challenges for the clinical applications of psychedelics

British Journal of Pharmacology, EarlyView.
Abstract The past decade has seen a huge increase in clinical research with psychedelic drugs and 3,4‐methylenedioxymethamphetamine (MDMA), which have revealed great potential for treating mental health conditions. Given this progress in research, as well as the current unmet clinical need of millions of patients, in 2023, the Australian Therapeutic ...
David J Nutt, Peter Hunt, Anne Katrin Schlag, Paul Fitzgerald   +3 more
wiley   +1 more source

Psilocybin as a novel treatment for chronic pain

British Journal of Pharmacology, EarlyView.
Abstract Psychedelic drugs are under active consideration for clinical use and have generated significant interest for their potential as anti‐nociceptive treatments for chronic pain, and for addressing conditions like depression, frequently co‐morbid with pain.
Tate Askey, Reena Lasrado, Maria Maiarú, Gary J. Stephens   +3 more
wiley   +1 more source

The void and the brain

Cell Reports
Blackburne et al. track the electroencephalogram activity of volunteers inhaling a high dose of the powerful psychedelic 5-methoxy-N,N-dimethyltryptamine, revealing profoundly slowed-down brain activity but no significant reduction of alpha band power ...
Christof Koch
doaj   +1 more source

Phenomenology and content of the inhaled N, N-dimethyltryptamine (N, N-DMT) experience

Scientific Reports, 2022
Understanding the phenomenology and content of the inhaled N, N, dimethyltryptamine (N, N-DMT) experience is critical to facilitate and support ongoing research and therapeutic models targeting mental health conditions and central nervous system ...
David Wyndham Lawrence, Robin Carhart-Harris, Roland Griffiths, Christopher Timmermann   +3 more
doaj   +1 more source

Neuropsychopharmacology of hallucinogenic and non‐hallucinogenic 5‐HT2A receptor agonists

British Journal of Pharmacology, EarlyView.
Psychedelic drugs such as LSD and psilocin were once relegated to the fringes of medical research because of their association with counterculture movements and a perceived concern about harm through recreational use, and their consequent legal prohibition in the early 1970s.
Trevor Sharp, Aurelija Ippolito
wiley   +1 more source

Modern Clinical Research on LSD [PDF]

, 2017
All modern clinical studies using the classic hallucinogen lysergic acid diethylamide (LSD) in healthy subjects or patients in the last 25 years are reviewed herein. There were five recent studies in healthy participants and one in patients.
A Garcia-Romeu, A Rickli, A Rickli, AB Wolbach Jr, AL Halberstadt, AL Halberstadt, Andrea E. Steuer, AV Lebedev, CM Hysek, CM Hysek, CS Grob, D Holland, D Marona-Lewicka, D Nutt, DB Terhune, DE Nichols, DE Nichols, DE Nichols, DV Sheehan, E Gouzoulis-Mayfrank, E Studerus, E Tagliazucchi, EA Schindler, F Hasler, F Mueller, FL Osorio, FX Vollenweider, FX Vollenweider, J Riba, J Seibert, J Speth, JC Bouso, JH Halpern, JJ Rucker, KA MacLean, KH Preller, KH Preller, KH Preller, KPC Kuypers, L Roseman, L Roseman, LD Simmler, LE Hollister, M Johnson, M Kaelen, M Kaelen, M Kometer, M Kometer, MA Geyer, Matthias E Liechti, ME Liechti, MJ Baggott, MP Bogenschutz, MW Johnson, P Gasser, P Gasser, P Strajhar, Patrick C. Dolder, PC Dolder, PC Dolder, PC Dolder, PS Hendricks, R Kraehenmann, Rainer Kraehenmann, RE Belleville, RG Dos Santos, RJ Strassman, RJ Strassman, RL Carhart-Harris, RL Carhart-Harris, RL Carhart-Harris, RL Carhart-Harris, RL Carhart-Harris, RL Carhart-Harris, RL Carhart-Harris, RR Griffiths, RR Griffiths, S Ross, SD Muthukumaraswamy, T Passie, TS Krebs, TS Krebs, WE Fantegrossi, WN Pahnke, WN Pahnke, Y Schmid   +85 more
core   +1 more source

Psychedelics, entactogens and psychoplastogens for depression and related disorders

British Journal of Pharmacology, EarlyView.
Currently, the most actively investigated rapidly acting antidepressants, anxiolytics and/or anti PTSD agents, include psychedelics e.g. psilocybin, LSD, N,N‐dimethyltryptamine, ayahuasca; non‐hallucinogenic entactogens, e.g. MDMA; psychoplastogens which rapidly promote neuroplasticity, e.g.
Daniel Hoyer
wiley   +1 more source

Natural Psychoplastogens As Antidepressant Agents

Molecules, 2020
Increasing prevalence and burden of major depressive disorder presents an unavoidable problem for psychiatry. Existing antidepressants exert their effect only after several weeks of continuous treatment.
Jakub Benko, Stanislava Vranková
doaj   +1 more source

Psychological variables implied in the therapeutic effect of ayahuasca: A contextual approach [PDF]

, 2018
Ayahuasca is a psychedelic decoction originating from Amazonia. The ayahuasca-induced introspective experience has been shown to have potential benefits in the treatment of several pathologies, to protect mental health and to improve neuropsychological ...
Alcázar Córcoles, Miguel Ángel, Bouso, José Carlos, Franquesa, Alba, Gandy, Sam, Sainz-Cort, Alberto, Soler, Joaquim   +5 more
core   +1 more source